Liquid Biopsy

DYNAMIC Trial: ctDNA-Guided Therapy Halves Chemotherapy Use in Stage II Colon Cancer Without Compromising Outcomes The New England journal of medicine 2022 Landmark-class ELN 2021 MRD Consensus Introduces NGS Specifications and Integrative Assessment for AML Blood 2021 Landmark-class Stockholm3 Blood Test Plus MRI Outperforms Standard PSA Screening for Prostate Cancer The Lancet. Oncology 2021 Landmark-class MRI-Targeted Biopsy Halves Clinically Insignificant Prostate Cancer Detection in Screening The New England journal of medicine 2021 Landmark-class ctDNA Identifies Urothelial Cancer Patients Who Benefit from Adjuvant Atezolizumab Nature 2021 Landmark-class Largest Ovarian Cancer Screening Trial Finds No Mortality Benefit After 16 Years Lancet (London, England) 2021 Landmark-class Multi-Site Benchmarking Study Defines Analytical Performance Boundaries of Leading ctDNA Assays Nature biotechnology 2021 Landmark-class Landmark Perspective Charts the Path from Approved Liquid Biopsy Assays to ctDNA-Guided Relapse Detection Nature reviews. Clinical oncology 2021 Landmark-class Meta-Analysis of 11,151 AML Patients Confirms MRD Negativity Nearly Doubles Survival JAMA oncology 2020 Landmark-class Lung-MAP Master Protocol Delivers Biomarker-Driven Results in Squamous NSCLC The Lancet. Oncology 2020 Landmark-class Implementing Plasma-Based ctDNA Genotyping in NSCLC Clinical Practice Nature reviews. Clinical oncology 2020 Landmark-class plasmaMATCH: ctDNA-Directed Therapy Platform Trial Validates Liquid Biopsy for Breast Cancer Genotyping The Lancet. Oncology 2020 Landmark-class Machine Learning Method Lung-CLiP Distinguishes Early Lung Cancer from Controls Using ctDNA Features Nature 2020 Landmark-class Ultra-Deep cfDNA Sequencing Reveals Clonal Haematopoiesis as the Dominant Source of Plasma Mutations Nature medicine 2019 Landmark-class CASSIOPEIA Trial Establishes Daratumumab-VTd as Standard Induction for Transplant-Eligible Myeloma Lancet (London, England) 2019 Landmark-class NEJM Review Establishes Clinical Framework for Cell-Free DNA Analysis in Cancer Treatment The New England journal of medicine 2018 Landmark-class Tisagenlecleucel CAR-T Therapy Achieves 81% Remission in Paediatric Relapsed ALL The New England journal of medicine 2018 Landmark-class Serum DNA methylation marker EFC#93 detects lethal breast cancer months before diagnosis Genome medicine 2017 Landmark-class Daratumumab-VMP Nearly Halves Disease Progression in Transplant-Ineligible Myeloma The New England journal of medicine 2017 Landmark-class Meta-Analysis Confirms MRD Negativity Predicts Superior Survival in Multiple Myeloma JAMA oncology 2017 Landmark-class ELN 2017 Recommendations Establish Genomic Risk Classification and MRD Framework for AML Blood 2016 Landmark-class Daratumumab Added to Lenalidomide-Dexamethasone Significantly Improves MRD Negativity in Relapsed Myeloma The New England journal of medicine 2016 Landmark-class Plasma ddPCR Detects EGFR and KRAS Mutations in Lung Cancer with 100% Positive Predictive Value JAMA oncology 2016 Landmark-class IMWG Consensus Criteria Define MRD Negativity as New Response Endpoint in Multiple Myeloma The Lancet. Oncology 2016 Landmark-class Inotuzumab Ozogamicin Achieves 81% Remission with Superior MRD Clearance in Relapsed ALL The New England journal of medicine 2016 Landmark-class NPM1 Mutation Tracking by RT-qPCR Is the Strongest Prognostic Factor in Standard-Risk AML The New England journal of medicine 2016 Landmark-class UKCTOCS: multimodal ovarian cancer screening shows 20% mortality reduction when prevalent cases excluded Lancet (London, England) 2015 Landmark-class Liquid Biopsy and Radiomics Show Promise for Lung Cancer Screening Beyond CT Nature reviews. Clinical oncology 2026 Landmark-class Postoperative ctDNA Predicts Celecoxib Benefit in Stage III Colon Cancer JAMA oncology 2026 Landmark-class Cell-Free DNA Model Detects Pancreatic Cancer Up to 298 Days Before Clinical Diagnosis Cancer discovery 2026 Landmark-class Nature Medicine Review Positions Liquid Biopsy Across the Full Cancer Care Continuum Nature medicine 2025 Landmark-class Focused Ultrasound Plus Temozolomide Achieves 31-Month Median Survival in Glioblastoma With Sono-Liquid Biopsy The Lancet. Oncology 2025 Landmark-class Non-Operative Management After Total Neoadjuvant Therapy Preserves Organs in Rectal Cancer Without Compromising Survival The Lancet. Oncology 2025 Landmark-class Epcoritamab Plus R2 Achieves 88% Complete Response and 86% MRD Negativity in Relapsed Follicular Lymphoma Blood 2025 Landmark-class Targeting Dormant Tumour Cells with Everolimus and Hydroxychloroquine Depletes Minimal Residual Disease in Breast Cancer Nature medicine 2025 Landmark-class Combined PET and ctDNA Response Predicts Early Progression in Follicular Lymphoma with 86% Positive Predictive Value Blood 2025 Landmark-class Early ctDNA Response Predicts Immunotherapy Outcomes in MSI-High Metastatic Colorectal Cancer JAMA oncology 2025 Landmark-class Isatuximab-Carfilzomib Quadruplet Induction Achieves 63% MRD Negativity in Newly Diagnosed Myeloma Blood 2025 Landmark-class Second Large Validation Study Confirms Blood-Based ctDNA Test Detects 79% of Colorectal Cancers JAMA 2025 Landmark-class Multi-Cancer Early Detection via Liquid Biopsy: Promises, Pitfalls, and What Comes Next Nature reviews. Clinical oncology 2025 Landmark-class New Colorectal Cancer Screening Methods: cfDNA Blood Tests and Improved Stool Biomarkers Nature reviews. Clinical oncology 2025 Landmark-class MURANO Final Analysis Shows 7-Year Durability of MRD-Guided Venetoclax-Rituximab in CLL Blood 2025 Landmark-class IMpassion031 Final Results: ctDNA Dynamics Add Prognostic Value Beyond Pathologic Response in TNBC Nature medicine 2025 Landmark-class ctDNA Fraction Predicts PSMA-Targeted Radioligand Therapy Response in Metastatic Prostate Cancer Nature medicine 2025 Landmark-class FLT3-ITD MRD Levels Predict Relapse and Guide Gilteritinib Maintenance After Transplant Blood 2025 Landmark-class Comprehensive Review Maps the cfDNA Fragmentome as a Multi-Feature Platform for Early Cancer Detection Nature reviews. Cancer 2025 Landmark-class Personalised Neoantigen Vaccine Targets Driver Mutations and Prevents Recurrence in Renal Cell Carcinoma Nature 2025 Landmark-class Daratumumab-Lenalidomide Maintenance Doubles MRD-Negative Conversion After Transplant in Myeloma Blood 2025 Landmark-class Baseline ctDNA Level and Early Clearance Predict Survival in Locally Advanced Rectal Cancer EBioMedicine 2025 Landmark-class CA-125 screening offers a 12-month window for early-stage ovarian cancer detection EBioMedicine 2025 Landmark-class Pantel and Alix-Panabieres Outline How ctDNA-Guided MRD Detection Could Enable Curative Post-Adjuvant Therapy Nature reviews. Clinical oncology 2024 Landmark-class cfDNA Fragmentome Blood Test Validated for Augmenting Lung Cancer Screening Cancer discovery 2024 Landmark-class Standing Platform Proposed for ctDNA-Guided Cancer Drug Development in Molecular Evidence of Disease Nature reviews. Cancer 2024 Landmark-class BEACON CRC Biomarker Analysis Reveals Resistance Mechanisms to BRAF-Targeted Therapy via ctDNA Profiling Nature medicine 2024 Landmark-class BRCA1/2 Testing in Males Demands Greater Clinical Attention Given Expanding Therapeutic Options JAMA oncology 2024 Landmark-class Systematic Review Validates Undetectable MRD as PFS Surrogate in CLL Treated with Targeted Agents JAMA oncology 2024 Landmark-class Peripheral Blood Mass Spectrometry Provides Non-Invasive MRD Assessment in Post-Transplant Myeloma Blood 2024 Landmark-class Postoperative ctDNA Positivity Strongly Predicts Recurrence in Resectable Pancreatic Cancer JAMA oncology 2024 Landmark-class ctDNA Outperforms Flow Cytometry for Early Relapse Detection in CLL Triple-Combination Therapy Blood 2024 Landmark-class ctDNA-Guided TKI De-Escalation in Advanced NSCLC Enables Median 9-Month Treatment Breaks JAMA oncology 2024 Landmark-class Five-Drug ViPOR Regimen Achieves Durable Remissions in Molecular Subtypes of Relapsed DLBCL The New England journal of medicine 2024 Landmark-class BFAST Trial Validates Liquid Biopsy-Guided Entrectinib for ROS1-Positive Lung Cancer Nature medicine 2024 Landmark-class CASSIOPEIA Long-Term Follow-Up Confirms Daratumumab Maintenance Benefit with MRD-Guided Monitoring The Lancet. Oncology 2024 Landmark-class Ponatinib Doubles MRD-Negative Complete Remission Rate Versus Imatinib in Ph+ ALL JAMA 2024 Landmark-class Adagrasib Plus Cetuximab Shows 34% Response Rate in KRASG12C-Mutated Colorectal Cancer Cancer discovery 2024 Landmark-class Donor-Derived Cell-Free DNA Validates as Noninvasive Biomarker for Kidney Transplant Rejection Nature medicine 2024 Landmark-class MRI Integration in Prostate Cancer Screening Halves Unnecessary Biopsies Without Missing Clinically Significant Cancer JAMA oncology 2024 Landmark-class Belantamab Mafodotin Combination Triples Progression-Free Survival in Relapsed Myeloma The New England journal of medicine 2024 Landmark-class ctDNA Dynamics Reveal Distinct Response Patterns to Immunotherapy vs Chemotherapy in Metastatic Urothelial Cancer Nature medicine 2024 Landmark-class Felzartamab Resolves Antibody-Mediated Kidney Transplant Rejection in Phase 2 Trial The New England journal of medicine 2024 Landmark-class Three-Step PSA-Kallikrein-MRI Protocol Detects More Aggressive Prostate Cancers With Less Overdiagnosis JAMA 2024 Landmark-class Expanded Prenatal cfDNA Screening Detects Aneuploidies, Microdeletions and Monogenic Variants in a Single Test Nature medicine 2024 Landmark-class Clinical Practice Guideline Establishes Standards for Blood-Based ctDNA Assays Annals of laboratory medicine 2024 Landmark-class KRAS-Targeted Amphiphile Vaccine Induces T Cell Responses and ctDNA Clearance in Pancreatic and Colorectal Cancer Nature medicine 2024 Landmark-class cfDNA-Based PreCar Score Doubles Early Hepatocellular Carcinoma Detection Sensitivity Versus Ultrasound EBioMedicine 2024 Landmark-class ctDNA Reveals KIT Mutation-Dependent Drug Sensitivity in GIST: INTRIGUE Trial Biomarker Analysis Nature medicine 2024 Landmark-class Multitarget Stool RNA Test Significantly Outperforms FIT for Colorectal Cancer and Advanced Adenoma Detection JAMA 2023 Landmark-class Sequential CD19 and CD22 CAR-T Therapy Achieves 97% Response and Durable MRD-Negative Remissions in Childhood B-ALL The Lancet. Oncology 2023 Landmark-class BR.36 Trial Validates ctDNA Molecular Response at Cycle 3 as Predictor of Pembrolizumab Outcome in NSCLC Nature medicine 2023 Landmark-class Phase 1 Trial of KRAS G12C Inhibitor Divarasib Shows Durable Responses with Serial ctDNA Monitoring The New England journal of medicine 2023 Landmark-class Liquid Biopsy-Guided Anti-EGFR Rechallenge Shows Benefit in Refractory RAS Wild-Type Colorectal Cancer JAMA oncology 2023 Landmark-class Early ctDNA Reduction Predicts Survival Benefit from Tebentafusp in Uveal Melanoma Nature medicine 2022 Landmark-class KEYNOTE-564 Update Confirms Adjuvant Pembrolizumab Benefit in Renal Cell Carcinoma at 30 Months The Lancet. Oncology 2022 Landmark-class INTEGA Trial: Nivolumab-Trastuzumab Plus FOLFOX Outperforms Ipilimumab Arm in ERBB2-Positive Gastric Cancer JAMA oncology 2022 Landmark-class Temozolomide Priming Induces Mismatch Repair Deficiency and Sensitises Colorectal Tumours to Immunotherapy Cancer discovery 2022 Landmark-class Ponte-di-Legno Consortium Establishes International Consensus on MRD-Based Response Definitions in Pediatric ALL Blood 2022 Landmark-class Sustained MRD Negativity Predicts Superior PFS in Transplant-Ineligible Myeloma Treated with Daratumumab Blood 2022 Landmark-class ctDNA Minimal Residual Disease Emerges as a Transformative Biomarker for Predicting Solid Tumour Relapse Cancer discovery 2021 Landmark-class ctDNA Genotyping Matches Tissue Testing for HER2-Amplified Colorectal Cancer Treatment Selection Nature medicine 2021 Landmark-class Large Phase 3 Trial Shows Vincristine-Dexamethasone Pulses Can Be Safely Omitted in Low-Risk Childhood ALL The Lancet. Oncology 2021 Landmark-class KTE-X19 CAR-T Achieves 71% Complete Remission with 97% MRD Negativity in Adult Relapsed ALL Lancet (London, England) 2021 Landmark-class Beyond Sequence: Epigenomics, Fragmentomics, and Topology Expand Cell-Free DNA Analysis Science (New York, N.Y.) 2021 Landmark-class Blinatumomab Outperforms Chemotherapy in Children with High-Risk First-Relapse B-ALL JAMA 2021 Landmark-class Ide-cel CAR-T Therapy Achieves 73% Response and 26% MRD Negativity in Heavily Pretreated Myeloma The New England journal of medicine 2021 Landmark-class Circulating Tumour DNA Validated as Independent Prognostic Biomarker in BRAF-Mutant Melanoma The Lancet. Oncology 2021 Landmark-class Universal Genetic Testing in Cancer Patients Finds 6% More Actionable Variants Than Guideline-Directed Testing JAMA oncology 2021 Landmark-class Lancet Seminar Defines the Diagnostic and MRD Landscape of Multiple Myeloma Lancet (London, England) 2021 Landmark-class Serial ctDNA Monitoring Predicts Treatment Response in KRAS-Mutant Metastatic Colorectal Cancer Clinical chemistry 2020 Landmark-class Chemotherapy-Free Dasatinib-Blinatumomab Strategy Yields 60% Molecular Response in Ph+ ALL The New England journal of medicine 2020 Landmark-class Combined ctDNA and CTC Detection After Neoadjuvant Chemotherapy Predicts Recurrence in Triple-Negative Breast Cancer JAMA oncology 2020 Landmark-class mRNA-1273 Vaccine Phase 1 Trial Demonstrates Robust Antibody and Neutralisation Response Against SARS-CoV-2 The New England journal of medicine 2020 Landmark-class NCI Whitepaper Defines ctDNA Applications Across Colorectal Cancer Management Nature reviews. Clinical oncology 2020 Landmark-class Plasma Tumor Mutation Burden Identifies Colorectal Cancer Patients Benefiting from Dual Checkpoint Inhibition JAMA oncology 2020 Landmark-class Tepotinib Achieves 46% Response Rate in MET Exon 14 Skipping NSCLC with Liquid and Tissue Biopsy Concordance The New England journal of medicine 2020 Landmark-class Clonal Hematopoiesis Complicates MRD Assessment in Acute Myeloid Leukemia Blood 2020 Landmark-class Mass Spectrometry Methods Transform M-Protein Detection and MRD Monitoring in Myeloma Clinical chemistry 2020 Landmark-class Pre-Transplant Molecular MRD Strongly Predicts Outcome in NPM1-Mutated AML Blood 2020 Landmark-class Post-Surgery and Post-Chemotherapy ctDNA Predicts Recurrence Risk in Stage III Colon Cancer JAMA oncology 2019 Landmark-class BMJ Guideline: FIT, Sigmoidoscopy, and Colonoscopy All Offer Similar Colorectal Cancer Mortality Reduction BMJ (Clinical research ed.) 2019 Landmark-class Personalised ctDNA Assays Detect Breast Cancer Molecular Relapse 10.7 Months Before Clinical Recurrence JAMA oncology 2019 Landmark-class Single-Cell CTC Profiling Reveals Tumour Heterogeneity Beyond What ctDNA Can Capture Nature reviews. Cancer 2019 Landmark-class Pantel and Alix-Panabieres Define Liquid Biopsy Technologies for Minimal Residual Disease Surveillance Nature reviews. Clinical oncology 2019 Landmark-class Preanalytical Guidelines for Circulating Cell-Free DNA Analysis: A Systematic Review Clinical chemistry 2019 Landmark-class NTRK Fusions in Cancer: Detection Strategies and Targeted TRK Inhibitor Therapy Nature reviews. Clinical oncology 2018 Landmark-class ctDNA as a Biomarker for Immunotherapy Response: Monitoring Pseudoprogression and Resistance Nature reviews. Clinical oncology 2018 Landmark-class Standard Clinical Chemistry Validation Protocols Successfully Applied to ddPCR Liquid Biopsy Assays Clinical chemistry 2018 Landmark-class PALOMA-3 ctDNA Analysis Maps Resistance Evolution to Palbociclib Plus Fulvestrant in Breast Cancer Cancer discovery 2018 Landmark-class BMJ guideline recommends against routine PSA screening for prostate cancer BMJ (Clinical research ed.) 2018 Landmark-class Meta-Analysis Questions Mortality Benefit of PSA-Based Prostate Cancer Screening BMJ (Clinical research ed.) 2018 Landmark-class ctDNA Shows Promise for Early NSCLC Screening and Post-Surgical MRD Detection Despite Technical Challenges Nature reviews. Clinical oncology 2018 Landmark-class Prenatal Cell-Free DNA Testing: How Genomic Screening Transformed Prenatal Care The New England journal of medicine 2018 Landmark-class ctDNA and MSI/EBV Status Predict Dramatic Responses to Pembrolizumab in Metastatic Gastric Cancer Nature medicine 2018 Landmark-class Clinical Genomics in Oncology: From Targeted Therapy to Mutational Load and Vaccine Design Nature reviews. Clinical oncology 2018 Landmark-class USPSTF Evidence Review: PSA Screening Reduces Mortality but Carries Substantial Overdiagnosis Risk JAMA 2018 Landmark-class Single PSA Test Does Not Reduce Prostate Cancer Deaths in UK CAP Trial at 10 Years JAMA 2018 Landmark-class USPSTF Review Confirms No Mortality Benefit From Ovarian Cancer Screening in Average-Risk Women JAMA 2018 Landmark-class Targeting Minimal Residual Disease Emerges as a Viable Path Toward Cancer Cure Nature reviews. Cancer 2018 Landmark-class Blinatumomab Achieves 78% Complete MRD Response in Adults with MRD-Positive ALL Blood 2018 Landmark-class Tumour Heterogeneity Drives Resistance: Implications for Liquid Biopsy Monitoring Nature reviews. Clinical oncology 2017 Landmark-class Liquid Biopsies for Early Cancer Detection: Promise and Biological Challenges NPJ precision oncology 2017 Landmark-class Anti-Inflammatory Drug Canakinumab Slashes Lung Cancer Incidence in CANTOS Trial Lancet (London, England) 2017 Landmark-class Meta-Analysis Confirms Strong Prognostic Value of MRD Negativity in Pediatric and Adult ALL JAMA oncology 2017 Landmark-class IFM 2009 Trial Confirms Transplant Advantage Over RVD Alone with MRD as Key Discriminator The New England journal of medicine 2017 Landmark-class Integrating Liquid Biopsies into Cancer Management: A Clinical Roadmap for ctDNA Nature reviews. Clinical oncology 2017 Landmark-class Landmark Review Charts the Path from ctDNA Research to Clinical Liquid Biopsy Nature reviews. Cancer 2017 Landmark-class EuroFlow Standardised 8-Colour Flow Cytometry Achieves 10-5 MRD Sensitivity in B-Cell ALL Blood 2016 Landmark-class Cord-Blood Transplants Yield Lower Relapse Rates Than Unrelated Donors in MRD-Positive Leukemia The New England journal of medicine 2016 Landmark-class Molecular Testing Challenges in Advanced NSCLC: From EGFR to PDL1 and Beyond Lancet (London, England) 2016 Landmark-class PET/CT Combined With Flow Cytometry MRD Improves Prognostic Stratification in Myeloma After Daratumumab Blood 2025 Significance 7/10 Mass Spectrometry Poised to Replace Electrophoresis for M-Protein Detection in Clinical Labs Annals of laboratory medicine 2025 Significance 7/10 PSA Variability Is High: 22% of Elevated Results Normalise Within a Year JAMA oncology 2025 Significance 7/10 Review Positions ctDNA-Based MRD Monitoring as Key to Personalising Unresectable Stage III NSCLC Therapy Nature reviews. Clinical oncology 2025 Significance 7/10 Default Mailed FIT Kit Outperforms Active Choice Strategies for Colorectal Screening in Younger Adults JAMA 2025 Significance 7/10 High-Dose Aumolertinib Shows Durable CNS Response in EGFR-Mutant NSCLC With Brain Metastases JAMA oncology 2025 Significance 7/10 Comprehensive Review Frames MRD as a Powerful but Incompletely Standardised Biomarker Across Haematologic Malignancies EClinicalMedicine 2025 Significance 7/10 BrECADD Preserves Fertility Significantly Better Than eBEACOPP in Advanced Hodgkin Lymphoma The Lancet. Oncology 2025 Significance 7/10 Extended Ibrutinib-Venetoclax Schedule Achieves 53% Undetectable MRD in Relapsed CLL Blood 2025 Significance 7/10 EFLM Conference Maps New Frontiers in Preanalytical Quality -- From AI to Liquid Biopsy Challenges Clinical chemistry and laboratory medicine 2025 Significance 7/10 SCLC Heterogeneity and Phenotypic Plasticity Demand New Biomarker Strategies Nature reviews. Cancer 2025 Significance 7/10 Review Maps Opportunities and Barriers for MRD-Guided Treatment in Multiple Myeloma Nature reviews. Clinical oncology 2025 Significance 7/10 European Liquid Biopsy Society Issues Consensus Guidelines for ctDNA Test Reporting EBioMedicine 2025 Significance 7/10 Zanubrutinib-Venetoclax-Obinutuzumab Achieves 85% Undetectable MRD in Relapsed CLL Blood 2025 Significance 7/10 Multicenter AIEOP-BFM Study Standardizes Flow Cytometry MRD Assessment in Pediatric T-ALL Clinical chemistry and laboratory medicine 2025 Significance 7/10 Adding a Return Deadline to FIT Invitation Letters Boosts Colorectal Screening Uptake Lancet (London, England) 2025 Significance 7/10 Chemo-Free BOVen Triplet Meets Efficacy Endpoint in TP53-Mutant Mantle Cell Lymphoma Blood 2025 Significance 7/10 ctDNA in Early and Locally Advanced NSCLC: Evidence Review and Clinical Readiness Assessment Nature reviews. Clinical oncology 2025 Significance 7/10 Frontline Large B-Cell Lymphoma Trials Increasingly Leverage ctDNA for Response-Adapted Strategies Blood 2025 Significance 7/10 Precision Imaging in Oncology: Bridging the Gap Between Liquid Biopsy and Treatment Monitoring The Lancet. Oncology 2025 Significance 7/10 Oral SERD Camizestrant Outperforms Fulvestrant in ER-Positive Advanced Breast Cancer The Lancet. Oncology 2024 Significance 7/10 Beyond pCR: Residual Disease Biology and ctDNA Refine Post-Neoadjuvant Strategy in Breast Cancer JAMA oncology 2024 Significance 7/10 Tepotinib Plus Osimertinib Achieves 50% Response Rate in MET-Amplified EGFR-Mutant NSCLC (INSIGHT 2) The Lancet. Oncology 2024 Significance 7/10 PROSPER Trial: Perioperative Nivolumab Fails to Improve Recurrence-Free Survival in Renal Cell Carcinoma The Lancet. Oncology 2024 Significance 7/10 Multiomics Profiling of Circulating Tumor Cells Reveals Metastatic Biology and Clinical Potential Cancer discovery 2024 Significance 7/10 DESTINY-Gastric01 Biomarker Analysis Reveals ctDNA and HER2 Heterogeneity Challenges in Gastric Cancer Nature medicine 2024 Significance 7/10 Neoadjuvant Immunotherapy in Esophageal Cancer: ctDNA Clearance Reflects Neoantigen-Specific T Cell Responses Nature medicine 2024 Significance 7/10 Systematic Review of Multi-Cancer Early Detection Tests: High Specificity, Variable Sensitivity Across 20 Studies Clinical chemistry 2024 Significance 7/10 Blood-Based Biomarkers for Lung Cancer Screening: Proteins, miRNA, cfDNA, and Methylation Panels Reviewed Clinical chemistry 2024 Significance 7/10 Practical Guide to Interpreting ctDNA in Gastrointestinal Cancer Management Clinical chemistry 2024 Significance 7/10 Review Identifies Critical Preanalytical and Analytical Variables in ctDNA Liquid Biopsy Workflows Clinical chemistry 2024 Significance 7/10 Extracellular Vesicle Biomarker Assays: Roadmap from Discovery to Clinical Implementation Clinical chemistry 2024 Significance 7/10 Sorafenib Plus Chemotherapy Does Not Improve Event-Free Survival in FLT3-ITD AML, but MRD Clearance Predicts Benefit Blood 2023 Significance 7/10 AI-Driven Digital Pathology and ctDNA Converge to Personalise Adjuvant Therapy in Colorectal Cancer Nature reviews. Clinical oncology 2023 Significance 7/10 Review Envisions MRD as Future Coprimary Endpoint and Treatment Adaptation Tool in Myeloma Blood 2023 Significance 7/10 GIVe Triple Combination Achieves Durable Remissions in High-Risk CLL With del(17p)/TP53 Mutation Blood 2023 Significance 7/10 Tumor Treating Fields Plus Standard Therapy Improves Survival in Metastatic NSCLC (LUNAR Phase 3) The Lancet. Oncology 2023 Significance 7/10 HPV Testing in Urine, Blood and Oral Specimens Gains Ground for Cancer Screening and Surveillance Journal of clinical microbiology 2023 Significance 7/10 New Genomic and Liquid Biopsy Insights Illuminate Richter Syndrome Transformation Blood 2023 Significance 7/10 Cell-Free RNA Fragments Outperform Other cfRNA Types for Early Hepatocellular Carcinoma Detection EBioMedicine 2023 Significance 7/10 Cholangiocarcinoma: cfDNA Monitoring Emerges Alongside FGFR2 and IDH1 Targeted Therapies Nature reviews. Clinical oncology 2023 Significance 7/10 Modelling Analysis Finds Modest Efficiency Gains for Polygenic Risk Score-Stratified Cancer Screening in the UK The Lancet. Oncology 2023 Significance 7/10 Belzutifan Plus Cabozantinib Shows Promising Activity in Pretreated Clear Cell Renal Cell Carcinoma The Lancet. Oncology 2023 Significance 7/10 CLEAR Trial Extended Follow-Up Confirms Durable PFS Benefit of Lenvatinib-Pembrolizumab in Renal Cell Carcinoma The Lancet. Oncology 2023 Significance 7/10 ATLAS Trial: Carfilzomib-Lenalidomide-Dexamethasone Maintenance Extends Progression-Free Survival in Myeloma After Transplant The Lancet. Oncology 2023 Significance 7/10 Cytogenetic Risk Stratification Reveals Unmet Need in Ultra-High-Risk Myeloma Despite Carfilzomib-Based Therapy The Lancet. Oncology 2022 Significance 7/10 Circulating Tumour Cell Biology Reveals New Cancer Vulnerabilities and Liquid Biopsy Opportunities Nature reviews. Cancer 2022 Significance 7/10 Mutation Enrichment Technologies Advance Low-Frequency Variant Detection for Liquid Biopsy Clinical chemistry 2022 Significance 7/10 International Consensus Prioritizes Molecular Biomarkers for Risk Stratification in Ewing Sarcoma NPJ precision oncology 2022 Significance 7/10 Clinical Trial Design Evolves for the Precision Oncology Era Genome medicine 2022 Significance 7/10 Personalized Neoantigen Vaccine Shows Promise in MSS Colorectal Cancer with ctDNA Response Correlation Nature medicine 2022 Significance 7/10 Beyond Blood: ctDNA from Urine, CSF, and Body Fluids Offers Distinct Diagnostic Advantages Nature reviews. Clinical oncology 2022 Significance 7/10 Nano-Omics: Nanotechnology-Enabled Multi-Omics Analysis of the Blood-Circulating Cancerome Nature reviews. Clinical oncology 2022 Significance 7/10 TERT Promoter Mutations Present in 60-80% of Bladder Cancers, Detectable Via Liquid Biopsy Human pathology 2022 Significance 7/10 ERBB2-Positive Metastatic Colorectal Cancer: Diagnostic Methods and Emerging Targeted Therapies JAMA oncology 2022 Significance 7/10 Lynch Syndrome Carriers With MSH2/MSH6 Mutations Show Higher Prostate Cancer Rates in IMPACT Screening Study The Lancet. Oncology 2021 Significance 7/10 Tumour-Educated Platelets Emerge as a Novel Liquid Biopsy Platform for Early Cancer Detection Blood 2021 Significance 7/10 General Health Checks Do Not Reduce Mortality but Boost Chronic Disease Detection JAMA 2021 Significance 7/10 Circulating Mitochondrial DNA Identified as a Proinflammatory DAMP in Sickle Cell Disease Blood 2021 Significance 7/10 ctDNA-Based Pan-Cancer Screening Tests Achieve Over 99% Specificity but Sensitivity Remains Stage-Dependent Clinical chemistry and laboratory medicine 2021 Significance 7/10 TRACERx Review: Tracking Cancer Evolution from Primary Disease Through Recurrence via Multiregion Sequencing Cancer discovery 2021 Significance 7/10 Liquid Biopsy Matures: A Framework for CTC and ctDNA Clinical Applications Cancer discovery 2021 Significance 7/10 Biomarker-Targeted Therapy Landscape in Gastric Cancer Expands Beyond HER2, MSI and PD-L1 Nature reviews. Clinical oncology 2021 Significance 7/10 ESOPE Trial: Profiling First Metastatic Event in Breast Cancer Reveals Actionable Heterogeneity Genome medicine 2021 Significance 7/10 Cancer of Unknown Primary: Molecular Tissue-of-Origin Tests and NGS Enter the Diagnostic Workup BMJ (Clinical research ed.) 2020 Significance 7/10 Bladder Cancer Review Highlights Liquid Biopsy and MRD Advances Nature reviews. Cancer 2020 Significance 7/10 Early-Onset Colorectal Cancer: Rising Incidence Demands New Screening and Biomarker Strategies Nature reviews. Clinical oncology 2020 Significance 7/10 mRNA-1273 Vaccine Elicits Strong Neutralising Antibody Responses in Older Adults The New England journal of medicine 2020 Significance 7/10 Next-Generation Sequencing in Clinical Laboratory Medicine: A Comprehensive Review Annals of laboratory medicine 2020 Significance 7/10 ENVISION Consensus Calls for Personalized Breast Cancer Screening Based on Multi-Factor Risk Models Nature reviews. Clinical oncology 2020 Significance 7/10 Circulating Tumour Cells: From Metastatic Biology to Clinical Liquid Biopsy Applications Genome medicine 2020 Significance 7/10 Switch-Blocker PCR Platform Achieves 93-96% Concordance with Tissue Biopsy for EGFR, BRAF, and KRAS ctDNA Journal of clinical pathology 2020 Significance 7/10 Epigenomic Approaches for Cancer Detection Using Tissue and Cell-Free DNA Clinical chemistry 2020 Significance 7/10 Liquid Biopsy Enters the Phenotypic Era With Single-Cell CTC Profiling Clinical chemistry 2020 Significance 7/10 Plasma miRNA Extraction Method Strongly Influences Biomarker Discovery Results, Multicenter Study Warns Clinical chemistry 2019 Significance 7/10 IMWG Consensus Standardises Imaging for Bone Disease and MRD Detection in Myeloma The Lancet. Oncology 2019 Significance 7/10 Designing ctDNA-Based Interventional Clinical Trials: A Framework for Oncology Genome medicine 2019 Significance 7/10 ctDNA Screening Selects Patients for Successful Anti-EGFR Rechallenge in Colorectal Cancer JAMA oncology 2019 Significance 7/10 Circulating Tumour Cells in Prostate Cancer: From Enumeration to Precision Oncology Clinical chemistry 2019 Significance 7/10 CSF ctDNA Clearance Correlates with Sustained Response in CNS Lymphoma Combination Therapy Trial Blood 2018 Significance 7/10 Plasma DNA Analysis in Prostate Cancer: Opportunities Across the Disease Spectrum Clinical chemistry 2018 Significance 7/10 Molecular Biomarkers for Guiding Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer The Lancet. Oncology 2018 Significance 7/10 EPA and aspirin fail to reduce colorectal adenoma rates in high-risk screening patients Lancet (London, England) 2018 Significance 7/10 Universal Cancer Screening Via Multi-Analyte Blood Tests: A Conceptual Framework NPJ precision oncology 2018 Significance 7/10 MRD Testing in CLL Evolves From Chemoimmunotherapy to Novel Targeted Agents JAMA oncology 2018 Significance 7/10 Triple BRAF/EGFR/MEK Inhibition Achieves 21% Response in BRAF V600E Colorectal Cancer with cfDNA Resistance Tracking Cancer discovery 2018 Significance 7/10 Leptomeningeal Metastases in NSCLC: Advances in CSF Liquid Biopsy and CNS-Penetrant Therapies The Lancet. Oncology 2018 Significance 7/10 Oncometabolites Bridge Inborn Errors of Metabolism and Cancer Diagnostics Clinical chemistry 2017 Significance 7/10 Colonoscopy outreach outperforms mailed FIT for completing cancer screening process JAMA 2017 Significance 7/10 EGFRvIII Vaccine Rindopepimut Fails to Improve Survival in Glioblastoma Despite MRD-Based Patient Selection The Lancet. Oncology 2017 Significance 7/10 High-Throughput Sequencing Enables Sensitive Noninvasive MRD Detection Across Hematologic Malignancies Blood 2017 Significance 7/10 IMWG Consensus Defines Role of PET/CT for MRD Assessment and Response Monitoring in Myeloma The Lancet. Oncology 2017 Significance 7/10 Technological Considerations for Clinical Cancer Genome Profiling: From FFPE to Liquid Biopsy Genome medicine 2016 Significance 7/10 Systematic review maps 788 blood-based biomarkers for early cancer detection EBioMedicine 2016 Significance 7/10 Enhanced reminder letters reduce socioeconomic gradient in bowel cancer screening uptake Lancet (London, England) 2015 Significance 7/10 Eliminating MRD as a Therapeutic Endpoint Could Move CLL Treatment Toward Cure Blood 2015 Significance 7/10 Liquid Biopsy Meets Mutational Signatures: A Framework for Longitudinal Cancer Monitoring NPJ precision oncology 2026 Significance 6/10 Review Highlights ctDNA as a Promising Risk Stratification Tool in Marginal Zone Lymphoma Blood 2026 Significance 6/10 Follicular Lymphoma Review Envisions ctDNA Replacing Imaging for Treatment Monitoring Blood 2025 Significance 6/10 Emerging Molecular Targets in Breast Cancer: From NGS and Liquid Biopsy to Spatial Transcriptomics Human pathology 2025 Significance 6/10 Comprehensive Review Maps ctDNA Treatment Monitoring Across Lung, Colorectal, and Breast Cancer NPJ precision oncology 2025 Significance 6/10 Expert Review Redefines ETP-ALL Management with MRD-Guided Risk Stratification Blood 2025 Significance 6/10 Review Examines MRD Monitoring and Molecular Biomarkers for Risk Stratification in Peripheral T-Cell Lymphoma Blood 2024 Significance 6/10 Expert Framework Calls for Standardized Neoadjuvant Biopsy Trials in Glioma Drug Development The Lancet. Oncology 2024 Significance 6/10 Comprehensive Review Maps Liquid Biopsy Landscape Across Pediatric Solid Tumors NPJ precision oncology 2024 Significance 6/10 Liquid Biopsy with miRNA and ctDNA Shows Promise for Gastric Cancer Screening and Treatment Monitoring Clinical biochemistry 2024 Significance 6/10 Circulating Tumour Cells in Breast Cancer: Current Clinical Validity and Emerging Utility Clinical chemistry 2024 Significance 6/10 Circulating Tumor Cells: From Metastatic Biology to Precision Medicine Applications Clinical chemistry 2024 Significance 6/10 ctDNA Implementation Challenges: From Early Detection to Immunotherapy Monitoring Clinical chemistry and laboratory medicine 2023 Significance 6/10 Global Lung Cancer Burden Underscores Need for Expanded Low-Dose CT Screening Programs Nature reviews. Clinical oncology 2023 Significance 6/10 Lucerne Toolbox 2: European Consensus on Axillary Lymph Node Management in Early Breast Cancer EClinicalMedicine 2023 Significance 6/10 Review Charts Genomic and Epigenetic Advances Transforming Oesophageal Cancer Detection and Treatment Nature reviews. Clinical oncology 2023 Significance 6/10 Urinary Cell-Free DNA Emerges as Truly Non-Invasive Alternative for Cancer Liquid Biopsy Clinical chemistry 2022 Significance 6/10 Women Disadvantaged in FIT-Based Colorectal Screening Due to Lower Faecal Haemoglobin Concentrations Clinical chemistry and laboratory medicine 2022 Significance 6/10 Circulating lncRNAs as Blood-Based Cancer Biomarkers: Diagnostic Performance and NGS Methods NPJ precision oncology 2022 Significance 6/10 Precision Diagnostics for Advanced Cutaneous Squamous Cell Carcinoma: Liquid Biopsy and Molecular Profiling NPJ precision oncology 2022 Significance 6/10 Circular RNAs Emerge as Cancer Biomarkers Detectable in Liquid Biopsy Nature reviews. Clinical oncology 2021 Significance 6/10 Tumor-Educated Platelets Emerge as Novel Liquid Biopsy Source for Cancer RNA Biomarkers Blood 2021 Significance 6/10 International consensus provides clinical toolbox for breast surgery after neoadjuvant therapy The Lancet. Oncology 2021 Significance 6/10 NGS and Flow Cytometry Reshape Treatment Paradigms in Acute Myeloid Leukemia Clinical pharmacology and therapeutics 2020 Significance 6/10 Circulating Tumour DNA in Molecular Oncology: Clinical Applications and Pre-Analytical Considerations Clinical chemistry and laboratory medicine 2020 Significance 6/10 Single-Cell Profiling of Circulating Tumour Cells Advances Liquid Biopsy Beyond Bulk Analysis NPJ precision oncology 2019 Significance 6/10 Pilot Ring Trial for Plasma ctDNA EGFR Mutation Testing Using Cobas Platform Clinical chemistry and laboratory medicine 2019 Significance 6/10 Tumor-Educated Platelets Emerge as a Distinct Liquid Biopsy Analyte Blood 2019 Significance 6/10 Circulating Tumor DNA as a Cancer Biomarker: Advantages Over Tissue and Protein Markers Annals of clinical biochemistry 2018 Significance 6/10 GSTP1 Methylation as a Liquid Biopsy Biomarker: Systematic Review Across Cancer Types Clinical chemistry and laboratory medicine 2018 Significance 6/10 Cell-Free DNA Across Body Fluids: Clinical Applications and Preanalytical Considerations for Molecular Pathology The Journal of pathology 2018 Significance 6/10 Cell-Free DNA Assays Move From Research to Routine Clinical Oncology Annals of laboratory medicine 2018 Significance 6/10 Translating Epigenetic Biomarkers From Discovery to Clinical Diagnostics: Challenges and Strategies Clinical chemistry and laboratory medicine 2017 Significance 6/10 Immunophenotypic and Genetic Profiling Essential for Risk Stratification in Adult T-Cell ALL Blood 2017 Significance 6/10 TIMPs as Extracellular Regulators of Cancer: From Tumour Biology to Liquid Biopsy Biomarkers Nature reviews. Cancer 2016 Significance 6/10 Circulating MicroRNAs as Blood-Based Cancer Biomarkers: Diagnostic and Screening Potential EBioMedicine 2016 Significance 6/10 Circulating Tumour Cell Isolation Technologies: From Biomarker-Dependent to Charge-Based Capture EBioMedicine 2022 Significance 5/10 Evidence on Repeat FIT Testing in Symptomatic Patients Remains Minimal and Conflicting Annals of clinical biochemistry 2022 Significance 5/10 Diabetes Lowers PSA Levels but the Difference Is Too Small to Affect Cancer Detection Clinical chemistry and laboratory medicine 2020 Significance 5/10 Patient-specific physician alerts modestly boost colorectal cancer screening uptake JAMA 2020 Significance 5/10 Liquid Biopsy in Gastrointestinal Cancer: From CTCs to ctDNA and Extracellular Vesicles Clinical biochemistry 2020 Significance 5/10 Caribbean Cancer Control Hampered by Weak Surveillance, Limited Diagnostics, and Advanced-Stage Presentations The Lancet. Oncology 2019 Significance 5/10 Pacific Island Nations Face Triple Cancer Burden With Fragmented Screening and Pathology Services The Lancet. Oncology 2019 Significance 5/10 GP notification of non-adherent patients increases FIT screening participation JAMA 2017 Significance 5/10 Whole-exome sequencing identifies PTEN hamartoma syndrome behind colorectal polyps Diagnostic pathology 2023 Significance 4/10